A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.
Anna V TinkerAlon D AltmanMarcus Q BernardiniPrafull GhatageLilian T GienDiane ProvencherShannon SalvadorSarah DoucetteAmit M OzaPublished in: Current oncology (Toronto, Ont.) (2022)
The majority of patients with advanced, high-grade epithelial-tubo ovarian cancer (EOC) respond well to initial treatment with platinum-based chemotherapy; however, up to 80% of patients will experience a recurrence. Poly(ADP-ribose) Polymerase (PARP) inhibitors have been established as a standard of care maintenance therapy to prolong remission and prevent relapse following a response to first-line platinum-chemotherapy. Olaparib and niraparib are the PARP inhibitors currently approved for use in the first-line maintenance setting in Canada. Selection of maintenance therapy requires consideration of patient and tumour factors, presence of germline and somatic mutations, expected drug toxicity profile, and treatment access. This paper discusses the current clinical evidence for first-line PARP inhibitor maintenance therapy in patients with advanced, high-grade EOC and presents consensus statements and a treatment algorithm to aid Canadian oncologists on the selection and use of PARP inhibitors within the Canadian EOC treatment landscape.
Keyphrases
- high grade
- dna damage
- dna repair
- low grade
- healthcare
- chronic kidney disease
- end stage renal disease
- radiation therapy
- newly diagnosed
- emergency department
- machine learning
- oxidative stress
- gene expression
- rheumatoid arthritis
- locally advanced
- chronic pain
- free survival
- copy number
- genome wide
- rectal cancer
- adverse drug